Spinal Pretreatment with Antisense Oligodeoxynucleotides against Exon-1, -4, or -8 of μ-Opioid Receptor Clone Leads to Differential Loss of Spinal Endomorphin-1-and Endomorphin-2-Induced Antinociception in the Mouse

  1. Hsiang-en Wu,
  2. Hirokazu Mizoguchi,
  3. Maia Terashvili,
  4. Randy J. Leitermann,
  5. Kuei-chun Hung,
  6. James M. Fujimoto and
  7. Leon F. Tseng
  1. Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin
  1. Dr. Leon F. Tseng, Department of Anesthesiology, Medical Education Bldg., Room M4308, Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI 53226. E-mail:ltseng{at}mcw.edu
 
Next Section

Abstract

Intrathecal (i.t.) pretreatments with antisense oligodeoxynucleotides (AS ODNs) against exon-1, -4, or -8 of μ-opioid receptor clone (MOR-1) to knockdown different variants of MOR-1 on the antinociception induced by endomorphin-1, enomorphin-2, or [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO) given i.t. were investigated in male CD-1 mice. The antinociception was measured with the tail-flick test. AS ODNs against exon-1 (5 μg) given i.t. once daily for 3 days attenuated the antinociception induced by endomorphin-1 and endomorphin-2 with the dose-response curves shifted to the right by 4.5- and 5.3-fold, respectively. AS ODNs against exon-4 (5 μg) attenuated the antinociception induced by endomorphin-1 and endomorphin-2 with the dose-response curves shifted to the right by 2.4- and 5.3-fold, respectively. However, AS ODNs against exon-8 (5 μg) attenuated only the antinociception induced by endomorphin-1, but not endomorphin-2 with the dose-response curves shifted to the right by 3.9- and 1.3-fold, respectively. One more day of pretreatment with antisense probes failed to further reduce the antinociception. The antinociception induced by DAMGO was attenuated by i.t. pretreatment with AS ODNs directed against exon-1, and, to a lesser extent, by AS ODNs directed against exon-8. The mismatch AS ODNs against respective exon-1, -4, and -8 failed to exert significant effects. The selective actions of antisense probes directed against different exons of the MOR-1 in attenuating the antinociception induced by endomorphin-1, endomorphin-2, and DAMGO suggest that multiple splice variants of the MOR-1 exist and support the view that different subtypes of μ-opioid receptors are involved in antinociception induced by endomorphin-1, endomorphin-2, and DAMGO.

Endomorphin-1 (Tyr-Pro-Trp-Phe-NH2) and endomorphin-2 (Tyr-Pro-Phe-Phe-NH2) are endogenous opioid peptides, which selectively bind and activate μ-opioid receptors (Zadina et al., 1997). In opioid receptor binding assays, both endomorphin-1 and endomorphin-2 compete with both μ1- and μ2-receptor sites very potently and have no appreciable affinities for δ- and κ1-receptors (Goldberg et al., 1998). Endomorphin-1 and endomorphin-2 activate G protein, which is mediated by stimulation of μ-opioid receptor, because the activation is selectively blocked by the μ-opioid receptor antagonists β-funaltrexamine (β-FNA) andd-Phe-Cys-Tyr-d-Trp-Orn-Thr-Pen-Thr-NH2(CTOP), but not by the δ-opioid receptor antagonist naltrindole or the κ-opioid receptor antagonist nor-binaltrophimine (nor-BNI) in the membrane preparation obtained from mouse spinal cord or periaqueductal central gray of the rat midbrain (Narita et al., 1998, 2000). Neither endomorphin-1 nor endomorphin-2 produces any G protein activation in the pons/medulla membrane preparation obtained from the μ-opioid receptor knockout mice (Mizoguchi et al., 1999). The specific actions of endo-morphin-1 and endomorphin-2 in stimulating μ-opioid receptors found in vitro are consistent with the in vivo antinociceptive studies with the tail-flick test in mice demonstrated that endomorphin-1 or endomorphin-2 when given i.t. or i.c.v. produced potent antinociception, which was blocked by the pretreatment with μ-opioid receptor antagonists naloxone, CTOP, or β-FNA (Stone et al., 1997;Goldberg et al., 1998; Tseng et al., 2000; Ohsawa et al., 2001). In μ-opioid receptor knockout mice or μ-opioid receptor-deficient CXBK mice, neither endomorphin-1 nor endomorphin-2 produces any significant antinociceptive effects (Mizoguchi et al., 1999). These findings strongly indicate that μ-opioid receptors play an essential role in mediating endomorphin-1- and endomorphin-2-induced antinociception.

Recent studies indicate that the antinociceptive effects induced by endomorphin-1 or endomorphin-2 given i.c.v. or i.t. are mediated by the stimulation of different subtypes of μ-opioid receptors. This view is supported by the findings that μ1-opioid receptor antagonist naloxonazine or morphine-6β-glucuronide antagonist 3-methoxynaltrexone blocks more effectively the antinociception induced by endomorphin-2 than by endomorphin-1 (Sakurada et al., 2000). The antinociception induced by endomorphin-1 is blocked by the pretreatment with μ-opioid receptor antagonists CTOP or β-FNA, but not κ-opioid receptor antagonist nor-BNI. On the other hand, the antinociception induced by endomorphin-2 is blocked by CTOP, β-FNA, or nor-BNI. Furthermore, the antinociception induced by endomorphin-2, but not endormorphin-1, is blocked by the pretreatment with antiserum against dynorphin A(1-17). The findings indicate that activation of the subtype of μ-opioid receptors by endomorphin-2 induces the release of dynorphin A(1-17), which subsequently stimulates the κ-opioid receptors for producing antinociception (Ohsawa et al., 2000, 2001; Tseng et al., 2000).

Antisense oligodeoxynucleotides (AS ODNs) have been used to knockdown gene expression and have proved to be useful pharmacological tools for studying neurotransmitter receptor activities in vitro and in vivo (Wahlestedt, 1993). The μ-opioid receptor MOR-1 was cloned after the δ-opioid receptor was cloned in the early 1990s (Evans et al., 1992;Chen et al., 1993). By antisense mapping of the MOR-1, 14 exons, exon-1 to -14, have been cloned and many splice variants of the MOR-1 have been identified (Rossi et al., 1997; Pan et al., 1999, 2000, 2001).Abbadie et al. (2000a) show that immunoreactivity of MOR-1, which contains exon-1, -2, -3, and -4, is observed only in the superficial laminae of spinal cord and MOR-1C, which contains exon-1, -2, -3, -7, -8, and -9, is abundant in the superficial laminae of the dorsal horn and around the central canal. The presence of MOR-1C in the superficial lamina of the spinal dorsal horn suggests that it plays a role in the pain control system. Different splice variants have been found in the central nervous system and the strikingly different distributions among different splice variants indicate that they may play different role in pain processing (Schulz et al., 1998; Abbadie et al., 2000b,c).

Morphine-induced antinociception is attenuated by pretreatment with AS ODNs directed against exon-1, -4, -6, -7, -8, -9, and -10, but is not affected by AS ODNs directed against exon-2 and -3, of MOR-1 (Neilan et al., 2001). On the other hand, the antinociception induced by morphine-6β-glucuronide is attenuated by AS ODNs directed against exon-2 but is unaffected by the pretreatment with AS ODNs directed against exon-1 or exon-4 to -10 (Neilan et al., 2001). AS ODNs targeting exon-1, but not exon-2 and -4 attenuate the antinociception induced by endomorphin-1 (Sanchez-Blazquez et al., 1999). Results from the antisense mapping studies suggest that those subtypes of μ-opioid receptors originally defined as μ1 and μ2 in binding and pharmacological studies result from alternative slicing of MOR-1 (Pasternak and Standifer, 1995; Pasternak, 2001). Present studies were designed to determine whether i.t. pretreatment with AS ODNs directed against various exons of MOR-1 might lead to differential loss of antinociception induced by endomorphin-1 and endomorphin-2. The selective μ-opioid receptor agonist DAMGO was also included for comparison.

Previous SectionNext Section

Materials and Methods

Animals.

Male CD-1 mice weighing 25 to 30 g (Charles River Laboratories, Inc., Wilmington, MA) were used. Animals were housed five per cage in a room maintained at 22 ± 0.5°C with an alternating 12-h light/dark cycle. Food and water were available ad libitum. All experiments were approved by and conformed to the guidelines of the Animal Care Committee of the Medical College of Wisconsin.

Assessment of Antinociception.

Antinociceptive responses were measured with the tail-flick test (D'Amour and Smith, 1941). To measure the latency of the tail-flick response, mice were gently held with the tail put on the apparatus (model TF6; EMDIE Instrument Co., Maidens, VA). The tail-flick response was elicited by applying radiant heat to the dorsal surface of the tail. The intensity of the heat stimulus was set to provide a predrug tail-flick response time of 3 to 4 s. The inhibition of the tail-flick response was expressed as percentage of maximum possible effect (%MPE), which was calculated as [(T1 −T0)/(T2− T0)] × 100.T0 andT1 were the tail-flick latencies before and after i.t. injection of endomorphin-1, endomorphin-2, or DAMGO and T2 was the cutoff time, which was set at 10 s. To establish the dose-response curves, at least four doses were used with 8 to 11 mice in each group.

Experimental Protocols.

Intrathecal injection (i.t.) was performed according to the procedure of Hylden and Wilcox (1980), using a 25-μl Hamilton syringe with a 30-gauge needle. The injection volume was 5 μl.

Groups of mice were pretreated i.t. once a day with AS ODNs directed against exon-1, -4, or -8 of MOR-1 (5 μg/5 μl) for 1, 2, 3, or 4 days and were challenged with endomorphin-1 (16.4 nmol) or endomorphin-2 (35.0 nmol) given i.t. 24 h after the last injection of the AS ODNs. The tail-flick responses were measured at 2.5, 5, 7.5, 10, 15, and 20 min thereafter. The peak tail-flick inhibition, which occurred at 2.5, 5, or 7.5 min after i.t. administration of endomorphin-1 or endomorphin-2, was used for the assessment of the antinociceptive effect. Five micrograms of AS ODNs was chosen for the study based on the information reported by others (Rossi et al., 1996;Schuller et al., 1999; Neilan et al., 2001) and the result of our preliminary study that this dose of AS ODNs against MOR-1-treated i.t. once daily for 3 days was sufficient to produce a maximal attenuation of endomorphin-1- or DAMGO-induced tail-flick inhibition. Groups of mice pretreated i.t. with mismatch AS ODNs against respective exon of MOR-1 or vehicle served as control. The ED50values for endomorphin-1 and endomorphin-2 for inhibiting the tail-flick response in mice pretreated once daily for 3 days with different AS ODNs against MOR-1 were determined. The effect of the pretreatment with AS ODNs against MOR-1 on antinociception induced by selective μ-opioid receptor agonist [d-Ala2,N-Me-Phe4,Gly-ol5]-enkephalin (DAMGO) was also studied for comparison.

Drugs.

Endomorphin-1 and endomorphin-2 were obtained from Calbiochem (La Jolla, CA). DAMGO was obtained from Bachem Biosciences (King of Prussia, PA). The endomorphin-1 and -2 for i.t. injections were dissolved in 0.9% saline containing 10% hydroxypropyl-β-cyclodextrin, and DAMGO was dissolved in saline containing 0.01% of Triton X-100.

Antisense Oligodeoxynucleotides.

Antisense ODNs against exon-1, -4, and -8 of MOR-1 were purchased from Midland Certified Reagent Company (Midland, TX). The antisense and mismatch ODNs sequences are shown in Table 1. Mismatch sequences of exon-1 is adapted from Neilan et al. (2001). Mismatch sequences of exon-4 and -8 of MOR-1 were designed in which two and three pairs, respectively, were reversed as a measure of the sequence-specificity of the antisense oligomer. A search of GeneBank showed that the mismatch sequence was not homologous to any known nontarget genes in the mouse. The ODNs were reconstituted in sterile saline and stored at −20°C for subsequent use.

View this table:
Table 1

Antisense and mismatch oligodeoxynucleotides sequence against MOR-1

Statistical Analysis.

The antinociceptive responses, %MPE, were presented as the mean ± S.E.M. A two-way analysis of variance followed by Bonferroni post tests was used to determine significance of the differences between the means. One evaluation involved determining the number of days (1–4 days) required to produce an effect by the daily pretreatment with the AS ODNs on endomorphins-induced antinociception. Another evaluation was to determine the selectivity produced by the pretreatment with AS ODNs against the antinociception produced by DAMGO. Nonlinear regression model was used to fit the dose-response curve. The dose-response curves, ED50 values, and their 95% confidence intervals were determined by using GraphPad Prism software (version 3.0; GraphPad Software, San Diego, CA). The F test was used to test the difference of ED50 between the endomorphins and vehicle.

Previous SectionNext Section

Results

Time Courses of Change of Tail-Flick Inhibition Induced by Endomorphin-1 and Endomorphin-2 Given i.t. after Once Daily i.t. Pretreatment with AS ODNs against Exon-1, -4, or -8 of MOR-1.

Endomorphin-1 (16.4 nmol) and endomorphin-2 (35.0 nmol) given i.t. produced 86 to 98, %MPE of the tail-flick inhibition in mice pretreated i.t. with vehicle or the mismatch ODNs against exon-1 of MOR-1 for 24 h. Repeated daily pretreatments with vehicle or the mismatch ODNs for 2 to 4 days did not significantly affect the tail-flick inhibition induced by endomorphin-1 or endomorphin-2. However, pretreatment with AS ODNs against exon-1of MOR-1 for 24 h significantly attenuated the tail-flick inhibition induced by i.t.-administered endomorphin-1 or endomorphin-2. The attenuation of the tail-flick inhibition induced by endomorphin-1 or endomorphin-2 was time-dependent and reached its lowest level at 37, %MPE after 3 days of i.t. pretreatment with AS ODNs against exon-1 of MOR-1 (Fig.1, A and B).

Figure 1
View larger version:
Figure 1

Time course of i.t. pretreatment with AS ODNs against exon-1 of MOR-1 on the inhibition of the tail-flick response induced by i.t.-administered endomorphin-1 (A) and endomorphin-2 (B), respectively. Groups of mice (8–10/group) were pretreated i.t. (5 μl each) with exon-1 AS ODNs (5 μg), mismatch ODNs (5 μg), or vehicle daily for 1, 2, 3, or 4 days before i.t. administration of endomorphin-1 (16.4 nmol) and endomorphin-2 (35.0 nmol), respectively. The peak tail-flick inhibition (%MPE) observed at 2.5, 5, or 7.5 min after i.t. administration of endomorphin-1 or endomorphin-2 was used to calculate the antinociceptive effect. Each column represents the mean and the vertical bar represents the S.E.M. Two-way ANOVA followed by Bonferroni's post test was used to test the difference between groups. ∗, p < 0.01; ∗∗, p < 0.001 compared with vehicle-injected groups; †, p< 0.01; ††, p < 0.001 compared with mismatch ODN-injected groups. ■, vehicle; ▧, exon-1 antisense; ▩, exon-1 mismatch.

Intrathecal pretreatment with AS ODNs against exon-4 of MOR-1 for 24 h significantly attenuated the tail-flick inhibition induced by endomorphin-1 but not by endomorphin-2. However, repeated once daily i.t. pretreatment with AS ODNs for 2 to 4 days time-dependently attenuated the tail-flick inhibition induced by endomorphin-1 or endomorphin-2. The attenuation of the tail-flick inhibition induced by i.t.-administered endomorphin-1 and endomorphin-2 reached its lowest level at 48 and 35, %MPE, respectively, after 3 days of pretreatment with the AS ODNs (Fig. 2, A and B). Repeated daily i.t. pretreatment with mismatch ODNs against exon-4 of MOR-1 for 1 to 4 days did not affect the tail-flick inhibition induced by i.t.-administered endomorphin-1 (16.4 nmol) or endomorphin-2 (35.0 nmol) compared with that of mice pretreated i.t. with vehicle.

Figure 2
View larger version:
Figure 2

Time course of i.t. pretreatment with AS ODNs against exon-4 of MOR-1 on the inhibition of the tail-flick response induced by i.t. administered endomorphin-1 (A) and endomorphin-2 (B), respectively. Groups of mice (8–11/group) were pretreated i.t. (5 μl each) with exon-4 AS ODNs (5 μg), mismatch ODNs (5 μg), or vehicle daily for 1, 2, 3, or 4 days before i.t. administration of endomorphin-1 (16.4 nmol) and endomorphin-2 (35.0 nmol), respectively, and the peak tail-flick inhibition (%MPE) observed at 2.5, 5, or 7.5 min after i.t. administration of endomorphin-1 or endomorphin-2 was used to calculate the antinociceptive effect. The difference between groups was as follows: ∗, p < 0.001 compared with vehicle-injected group; †, p < 0.01; ††,p < 0.001 compared with mismatch ODN-injected groups. ■, vehicle; ▧, exon-4 antisense; ▩, exon-4 mismatch.

Intrathecal pretreatment with AS ODNs against exon-8 of MOR-1 for 1 to 4 days time-dependently attenuated the tail-flick inhibition induced by i.t.-administered endomorphin-1 and the attenuation of the endomorphin-1-induced tail-flick inhibition reached its lowest level at about 39, %MPE after 3 days of pretreatment. However, the same treatment with AS ODNs against exon-8 of MOR-1 for 1 to 3 days did not affect the tail-flick inhibition induced by endomorphin-2 and only caused a slight attenuation of the tail-flick inhibition after 4 days of the pretreatment compared with vehicle group (Fig.3, A and B). Repeated once daily i.t. pretreatment with mismatch ODNs against exon-8 of MOR-1 for 1 to 4 days did not affect the tail-flick inhibition induced by i.t.-administered endomorphin-1 (16.4 nmol) or endomorphin-2 (35.0 nmol) compared with that of mice pretreated i.t. with vehicle.

Figure 3
View larger version:
Figure 3

Time course of i.t. pretreatment with AS ODNs against exon-8 of MOR-1 on the inhibition of the tail-flick response induced by i.t.-administered endomorphin-1 (A) and endomorphin-2 (B), respectively. Groups of mice (8–11/group) were pretreated i.t. (5 μl each) with exon-8 AS ODNs (5 μg), mismatch ODNs (5 μg), or vehicle daily for 1, 2, 3, or 4 days before i.t. administration of endomorphin-1 (16.4 nmol) and endomorphin-2 (35.0 nmol), respectively, and the peak tail-flick inhibition (%MPE) observed at 2.5, 5, or 7.5 min after i.t. administration of endomorphin-1 or endomorphin-2 was used to calculate the antinociceptive effect. The difference between groups was as follows: ∗, p < 0.05; ∗∗,p < 0.001 compared with vehicle-injected groups; †, p < 0.001compared with mismatch ODN-injected groups. ■, vehicle; ▧, exon-8 antisense; ▩, exon-8 mismatch.

Dose-Response Relationships for i.t.-Administered Endomorphin-1- and Endomorphin-2-Induced Tail-Flick Inhibition in Mice Pretreated i.t. with AS ODNs against Exon-1, -4, or -8 of MOR-1 Once a Day for 3 Days.

Groups of mice were pretreated i.t. with AS ODNs against exon-1, -4, or -8 of MOR-1 (5 μg/5 μl) once a day for 3 days and were injected i.t. with various doses of endomorphin-1 or endomorphin-2 24 h after the last injection of AS ODNs. Endomorphin-1 at doses from 1.6 to 16.4 nmol and endomorphin-2 at doses from 1.8 to 35.0 nmol dependently inhibited the tail-flick response in mice pretreated with vehicle. Intrathecal pretreatment with AS ODNs directed against exon-1 of MOR-1 markedly attenuated the tail-flick inhibitions induced by endomorphin-1 or endomorphin-2. The dose-response curves of endomorphin-1- and endomorphin-2-induced tail-flick inhibition were shifted to right by 4.54- and 5.33-fold, respectively, compared with the corresponding groups of mice pretreated with vehicle (Fig.4A; Table2).

Figure 4
View larger version:
Figure 4

Dose-response curves for the inhibition of the tail-flick response induced by i.t.-administered endomorphin-1 and endomorphin-2 in mice pretreated with vehicle, and AS ODNs against exon-1 (A), -4 (B), or -8 (C) of MOR-1. Groups of mice (8–10/group) were pretreated i.t. (5 μl each) with vehicle or different AS ODNs (5 μg) daily for 3 days against MOR-1 before i.t. injection with various doses of endmorphin-1 or endomorphin-2, and tail-flick responses were measured. The peak tail-flick inhibition (%MPE) observed at 2.5, 5, or 7.5 min after i.t. administration of endomorphin-1 or endomorphin-2 was used to calculate the antinociceptive effect. Each point represents the mean and the vertical bar represents the S.E.M. Nonlinear regression model was used to fit the log dose-response curve.

View this table:
Table 2

ED50 values of endomorphin-1 and -2 for tail-flick inhibition in mice pretreated with vehicle, exon-1, -4, or -8 MOR-1 antisense oligodeoxynucleotides

Intrathecal pretreatment with AS ODNs against exon-4 of MOR-1 attenuated the antinociception induced by endomorphin-1 and, to a greater extent, by endomorphin-2 and shifted the dose-response curves of endomorphin-1- and endomophin-2-induced tail-flick inhibition to the right by 2.44- and 5.28-fold, respectively, compared with the groups of mice pretreated with vehicle (Fig. 4B; Table 2).

Intrathecal pretreatment with AS ODNs against exon-8 of MOR-1 attenuated markedly the tail-flick inhibition induced by endomorphin-1 and caused the dose-response curve of endomorphin-1-induced tail-flick inhibition shifted to right by 3.92-fold compared with groups of mice pretreated with vehicle (Fig. 4C; Table 2). However, i.t. pretreatment with AS ODNs against exon-8 of MOR-1 did not cause any significant change of the antinociception induced by endomorphin-2 and the dose-response curve and ED50 value for endomorphin-2 were not affected by the pretreatment (Fig. 4C; Table 2).

Tail-Flick Inhibition Induced by i.t.-Administered DAMGO in Mice Pretreated i.t. with AS ODNs against Exon-1, -4, or -8 of MOR-1 for 3 Days.

Groups of mice were pretreated i.t. with AS ODNs against exon-1, -4, or -8 of MOR-1 (5 μg/5 μl) once a day for 3 days and were injected i.t. with DAMGO (0.02 nmol) 24 h after the last injection of the AS ODNs. The tail-flick responses were measured at various times after the injection. The peak tail-flick inhibition measured at 5, 10, or 15 min was used to calculate the antinociceptive effect. Other groups of mice pretreated i.t. with vehicle or mismatch ODNs against respective exon-1, -4, and -8 of MOR-1 served as controls. Intrathecal injection of 0.02 nmol of DAMGO produced 80 to 90% MPE of the tail-flick inhibition in mice pretreated with vehicle. Intrathecal pretreatment with mismatch AS ODNs against exon-1, -4, or -8 of MOR-1 did not affect the DAMGO-induced tail-flick inhibition compared with groups of mice pretreated with vehicle. However, the DAMGO-induced tail-flick inhibition was markedly attenuated by i.t. pretreatment with AS ODNs against exon-1 of MOR-1 and, to a lesser extent, by the AS ODNs against exon-8 of MOR-1 (Fig. 5).

Figure 5
View larger version:
Figure 5

Inhibition of the tail-flick response induced by i.t.-administered DAMGO in mice pretreated with vehicle, AS ODNs, and mismatch ODNs against exon-1, exon-4, or exon-8 of MOR-1, respectively. Groups of mice (8–10/group) were pretreated i.t. (5 μl each) with vehicle, antisense ODNs, or mismatch ODNs (5 μg) daily for 3 days against MOR-1 before i.t. injection with DAMGO, and the tail-flick responses were measured. The peak tail-flick inhibition (%MPE) observed at 5, 10, or 15 min after i.t. administration of DAMGO was used to calculate the antinociceptive effect. The difference between group: ∗, p < 0.01; ∗∗,p < 0.001 compared with vehicle-injected groups; †, p < 0.05; ††, p < 0.001 compared with mismatch ODN-injected groups. ■, vehicle; ▧, antisense; ▩, mismatch.

Previous SectionNext Section

Discussion

The antinociception induced by endomorphin-1 and endomorphin-2 has been demonstrated to be selectively mediated by the stimulation of μ-opioid receptors. This is evidenced by the finding that the tail-flick inhibition induced by endomorphin-1 and endomorphin-2 when given i.t. or i.c.v. is blocked by the pretreatment with selective μ-opioid receptor antagonists naloxone, CTOP, or β-FNA (Stone et al., 1997; Goldberg et al., 1998; Tseng et al., 2000; Ohsawa et al., 2001). However, recent studies indicate that the antinociceptive effects induced by endomorphin-1 and endomorphin-2 given i.c.v. or i.t. are mediated by the stimulation of different subtypes of μ-opioid receptors (Tseng et al., 2000; Ohsawa et al., 2001).

We found in the present studies that i.t. pretreatment of mice with AS ODNs against exon-1, -4, or -8 of MOR-1 differentially attenuated the antinociception induced by i.t.-administered endomorphin-1, endomorphin-2, or DAMGO. Pretreatment with AS ODNs against exon-1 of MOR-1 for 3 days was about equally effective in attenuating the antinociception induced by endomorphin-1, endomorphin-2, or DAMGO. However, pretreatment with AS ODNs against exon-4 for 3 days was more effective in attenuating the antinociception induced by endomorphin-1 and endomorphin-2, and was much less effective in attenuating the antinociception induced by DAMGO. On the other hand, pretreatment with AS ODNs against exon-8 of MOR-1 for 3 days was found to be more effective in attenuating the antinociception induced by endomorphin-1 and, to a lesser extent, by DAMGO, but showed no effect in attenuating the antinociception induced by endomorphin-2. Our results strongly suggest the presence of multiple μ-opioid receptors, which are differentially stimulated by endomorphin-1, endomorphin-2, and DAMGO to produce antinociception.

The results of our finding are consistent in part with a previous report by Sanchez-Blazquez et al. (1999), in which pretreatment with AS ODNs against exon-1, but not exon-2 or exon-4, of MOR-1 given i.c.v. attenuates the antinociception induced by endomorphin-1. We found in the present study that antinociception induced by endomorphin-1 was attenuated by i.t. pretreatment with AS ODNs against not only exon-1 but also exon-4 and -8 of MOR-1. The different effect of AS ODNs against exon-4 on endomorphin-1 between the present study andSanchez-Blazquez et al. (1999) may be due to by different sites of administration (i.t. in our experiment versus i.c.v. in Sanchez-Blazquez's experiment), different protocol used for AS ODNs treatment, or different dose of endomorphin-1 used (16.4 nmol in the present study versus 6.5 nmol in Sanchez-Blazquez's experiment).

We found that the antinociception induced by endomorphin-2 was attenuated by i.t. pretreatment with AS ODNs against exon-1 or exon-4, but not by exon-8 of MOR-1. Rossi et al. (1996, 1997) demonstrated that antinociception induced by heroin and morphine-6β-glucuronide is attenuated by AS ODNs against exon-2 or exon-3, but not by exon-1 or exon-4. The antinociception induced by morphine is attenuated by AS ODNs against exon-1 and most of the other exons except exon-2 (Neilan et al., 2001). Thus, the receptors stimulated by endomorphin-2 for producing antinociception are different from that of receptors stimulated by heroin or morphine-6β-glucuronide. The results of the present study with AS ODNs against various exons of MOR-1 are in line with our previous pharmacological studies, which indicate the presence of a noval μ-opioid receptor subtype responsible for endomorphin-2 to produce antinociception (Tseng et al., 2000; Ohsawa et al., 2001; Wu et al., 2001). The multiple μ-opioid receptors for endomorphin-1, endomorphin-2, and other μ-opioids may result from alternatively spliced variants of exons of MOR-1 (Pan et al., 1999, 2001).

Antinociception induced by endomorphin-1 and endomorphin-2 seems to be mediated by the stimulation of two different subtypes of μ-opioid receptors. It has been proposed that one subtype of μ-opioid receptors is stimulated by both endomorphin-1 and endomorphin-2 and another subtype of μ-opioid receptors is stimulated solely by endomorphin-2 (Tseng et al., 2000; Ohsawa et al., 2001). This view is further supported by the findings that μ1-opioid receptor antagonist naloxonazine blocks more effectively the antinociception induced by endomorphin-2 than endomorphin-1 and morphine-6β-glucuronide antagonist 3-methoxynaltrexone blocks endomorphin-2-induced antinociception without affecting endomorphin-1-induced antinociception given i.t (Sakurada et al., 2000). There is an asymmetric cross-tolerance between endomorphin-1 and endomorphin-2 for producing antinocicpeption. Mice made acute tolerant to endomorphin-1 are not cross-tolerant to endomorphin-2, whereas mice made tolerant to endomorphin-2 are partially cross-tolerant to endomorphin-1 (Wu et al., 2001). The antinociception induced by endomorphin-1 is blocked by μ-opioid receptor antagonists CTOP or β-FNA but not by κ-opioid antagonist nor-BNI. On the other hand, the antinociception induced by endomorphin-2 is blocked by CTOP, β-FNA, or nor-BNI (Tseng et al., 2000; Ohsawa et al., 2001).

We found in the present study that the antinociception induced by DAMGO was effectively attenuated by the pretreatment with AS ODNs against exon-1, but is much less effected by pretreatment with AS ODNs directed against exon-4 or exon-8. The results are consistent in general with the finding by others (Rossi et al., 1996; Leventhal et al., 1997;Sanchez-Blazquez et al., 1999).

It is concluded that mice pretreated i.t. with AS ODNs against exon-1, -4, or -8 of MOR-1 attenuated the antinociception induced by endomorphin-1. However, only AS ODNs against exon-1 or -4, but not exon-8, of MOR-1 attenuated the antinociception induced by endomorphin-2. The antinociception induced by DAMGO was attenuated by i.t. pretreatment of AS ODNs directed against exon-1 or -8, but not exon-4, of MOR-1. We therefore propose that distinct subtypes of μ-opioid receptors, which reflect different splice variants of exons of MOR-1, are involved in antinociceptive response induced by endomorphin-1, endomorphin-2, and DAMGO.

Previous SectionNext Section

Footnotes

  • This work was supported by Grant DA 03811 from the National Institutes of Health, National Institute on Drug Abuse (to L.F.T.). A preliminary report of these results was presented at the 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL, November 2–7, 2002.

  • DOI: 10.1124/jpet.102.038810

  • Abbreviations:
    β-FNA
    β-funaltrexamine
    CTOP
    d-Phe-Cys-Tyr-d-Trp-Orn-Thr-Pen-Thr-NH2
    nor-BNI
    nor-binaltrophimine
    AS ODN
    antisense oligodeoxynucleotide
    MOR
    μ-opioid receptor
    %MPE
    percentage of maximum possible effect
    DAMGO
    [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin
    ODN
    oligodeoxynucleotide
    • Received May 15, 2002.
    • Accepted August 2, 2002.
Previous Section
 

References

  1. ↵
    1. Abbadie C,
    2. Gultekin SH,
    3. Pasternak GW
    (2000a) Immunohistochemical localization of the carboxy terminus of the novel μ opioid receptor splice variant MOR-1C within the human spinal cord. Neuroreport 11:1953–1957.
    Medline
  2. ↵
    1. Abbadie C,
    2. Pan YX,
    3. Drake CT,
    4. Pasternak GW
    (2000b) Comparative immunohistochemical distributions of carboxy terminus epitopes from the μ-opioid receptor splice variants MOR-1D, MOR-1 and MOR-1C in the mouse and rat CNS. Neuroscience 100:141–153.
    CrossRefMedline
  3. ↵
    1. Abbadie C,
    2. Pan YX,
    3. Pasternak GW
    (2000c) Differential distribution in rat brain of μ opioid receptor carboxy terminal splice variants MOR-1C-like and MOR-1-like immunoreactivity: evidence for region-specific processing. J Comp Neurol 419:244–256.
    CrossRefMedlineWeb of Science
  4. ↵
    1. Chen Y,
    2. Mestek A,
    3. Lin Y,
    4. Hurley JA,
    5. Yu L
    (1993) Molecular cloning and functional expression of a μ-opioid receptor from rat brain. Mol Pharmacol 44:8–12.
    Abstract
  5. ↵
    1. D'Amour FE,
    2. Smith DL
    (1941) A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74–79.
    Abstract/FREE Full Text
  6. ↵
    1. Evans CJ,
    2. Keith DF,
    3. Morrison H,
    4. Magendzo K,
    5. Edwards RH
    (1992) Cloning of a δ receptor by functional expression. Science (Wash DC) 258:1952–1955.
    Abstract/FREE Full Text
  7. ↵
    1. Goldberg IE,
    2. Rossi GC,
    3. Letchworth SR,
    4. Mathis JP,
    5. Ryan-Moro J,
    6. Leventhal L,
    7. Su W,
    8. Emmel D,
    9. Bolan EA,
    10. Pasternak GW
    (1998) Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. J Pharmacol Exp Ther 286:1007–1013.
    Abstract/FREE Full Text
  8. ↵
    1. Hylden JLK,
    2. Wilcox GL
    (1980) Intrathecal morphine in mice: a new technique. Eur J Pharmacol 167:313–316.
  9. ↵
    1. Leventhal L,
    2. Stevens LB,
    3. Rossi GC,
    4. Pasternak GW,
    5. Bodnar R
    (1997) Antisense mapping of the MOR-1 opioid receptor clone: modulation of hyperphagia induced by DAMGO. J Pharmacol Exp Ther 282:1402–1407.
    Abstract/FREE Full Text
  10. ↵
    1. Mizoguchi H,
    2. Narita M,
    3. Oji DE,
    4. Suganuma C,
    5. Nagase H,
    6. Sora I,
    7. Uhl GR,
    8. Cheng EY,
    9. Tseng LF
    (1999) The μ-opioid receptor gene dose-dependent reductions in G-protein activation in the pons/medulla and antinociception induced by endomorphins in μ-opioid receptor knockout mice. Neuroscience 94:203–207.
    CrossRefMedline
  11. ↵
    1. Narita M,
    2. Mizoguchi H,
    3. Oji GS,
    4. Tseng EL,
    5. Suganuma C,
    6. Nagase H,
    7. Tseng LF
    (1998) Characterization of endomorphin-1 and -2 on [35S]GTPγS binding in the mouse spinal cord. Eur J Pharmacol 351:383–387.
    CrossRefMedlineWeb of Science
  12. ↵
    1. Narita M,
    2. Mizoguchi H,
    3. Narita M,
    4. Dun NJ,
    5. Hwang BH,
    6. Endoh T,
    7. Suzuki T,
    8. Nagase H,
    9. Suzuki T,
    10. Tseng LF
    (2000) G protein activation by endomorphins in the mouse periaqueductal gray matter. J Biomed Sci 7:221–225.
    CrossRefMedlineWeb of Science
  13. ↵
    1. Neilan CL,
    2. Nguyen TMD,
    3. Schiller PW,
    4. Pasternak GW
    (2001) Pharmacological characterization of the dermorphin analog [Dmt1]DALDA, a highly potent and selective μ-opioid peptide. Eur J Pharmacol 419:15–23.
    CrossRefMedline
  14. ↵
    1. Ohsawa M,
    2. Mizoguchi H,
    3. Narita M,
    4. Chu M,
    5. Nagase H,
    6. Tseng LF
    (2000) Differential mechanisms mediating descending pain controls for antinociception induced by supraspinally administered endomorphin-1 and endomorphin-2 in the mouse. J Pharmacol Exp Ther 294:1106–1111.
    Abstract/FREE Full Text
  15. ↵
    1. Ohsawa M,
    2. Mizoguchi H,
    3. Narita M,
    4. Nagase H,
    5. Kampine JP,
    6. Tseng LF
    (2001) Different antinociception induced by spinally administered endomorphin-1 and endomorphin-2 in the mouse. J Pharmacol Exp Ther 298:592–597.
    Abstract/FREE Full Text
  16. ↵
    1. Pan Y,
    2. Xu J,
    3. Bolan E,
    4. Abbadie C,
    5. Chang A,
    6. Zuckerman A,
    7. Rossi G,
    8. Pasternak GW
    (1999) Identification and characterization of three new alternatively spliced μ-opioid receptor isoforms. Mol Pharmacol 56:396–403.
    Abstract/FREE Full Text
  17. ↵
    1. Pan Y,
    2. Xu J,
    3. Bolan E,
    4. Chang A,
    5. Mahurter L,
    6. Rossi G,
    7. Pasternak GW
    (2000) Isolation and expression of a novel alternatively spliced μ opioid receptor isoform, MOR-1F. FEBS Lett 466:337–340.
    CrossRefMedline
  18. ↵
    1. Pan Y,
    2. Xu J,
    3. Mahurter L,
    4. Bolan E,
    5. Xu M,
    6. Pasternak GW
    (2001) Generation of the μ opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene. Proc Natl Acad Sci USA 98:14084–14089.
    Abstract/FREE Full Text
  19. ↵
    1. Pasternak GW
    (2001) Incomplete cross tolerance and multiple μ opioid peptide receptors. Trends Pharmacol Sci 22:67–70.
    Medline
  20. ↵
    1. Pasternak GW,
    2. Standifer KM
    (1995) Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. Trends Pharmacol Sci 16:344–350.
    CrossRefMedline
  21. ↵
    1. Rossi GC,
    2. Brown GP,
    3. Leventhal L,
    4. Yang K,
    5. Pasternak GW
    (1996) Novel receptor mechanisms for heroin and morphine-6β-glucuronide analgesia. Neurosci Lett 216:1–4.
    CrossRefMedlineWeb of Science
  22. ↵
    1. Rossi GC,
    2. Leventhal L,
    3. Pan Y-X,
    4. Cole J,
    5. Su W,
    6. Bodnar RJ,
    7. Pasternak GW
    (1997) Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6β-glucuronide antinociception. J Pharmacol Exp Ther 281:109–114.
    Abstract/FREE Full Text
  23. ↵
    1. Sakurada S,
    2. Hayashi T,
    3. Yuhki M,
    4. Fujimura T,
    5. Murayama K,
    6. Yonezawa A,
    7. Sakurada C,
    8. Takeshita M,
    9. Zadina JE,
    10. Kastin AJ,
    11. et al.
    (2000) Different antagonism of endomorphin-1 and endomorphin-2 spinal antinociception by naloxonazine and 3-methoxynaltrexone. Brain Res 881:1–8.
    CrossRefMedlineWeb of Science
  24. ↵
    1. Sanchez-Blazquez P,
    2. DeAntonia I,
    3. Rodriguez-Diaz M,
    4. Garzon J
    (1999) Antisense oligodeoxynucleotides targeting distinct exons of the cloned μ-opioid receptor distinguish between endomorphin-1 and morphine supraspinal antinociception in mice. Antisense Nucleic Acid Drug Dev 9:253–260.
    Medline
  25. ↵
    1. Schuller AGP,
    2. King MA,
    3. Zhang J,
    4. Bolan E,
    5. Pan YX,
    6. Morgan DJ,
    7. Chang A,
    8. Czick ME,
    9. Unterwald EM,
    10. Pasternak GW,
    11. et al.
    (1999) Retention of heroin and morphine-6β-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci 2:151–156.
    CrossRefMedlineWeb of Science
  26. ↵
    1. Schulz S,
    2. Schreff M,
    3. Koch T,
    4. Zimprich A,
    5. Gramsch C,
    6. Elde R,
    7. Hollt V
    (1998) Immunolocalization of two μ-opioid receptor isoforms (MOR1 and MOR1B) in the rat central nervous system. Neuroscience 82:613–622.
    CrossRefMedlineWeb of Science
  27. ↵
    1. Stone LS,
    2. Fairbanks CA,
    3. Laughlin TM,
    4. Nguyen HO,
    5. Bushy TM,
    6. Wessendorf MW,
    7. Wilcox GL
    (1997) Spinal analgesic actions of the new endogenous opioid peptides endomorphin-1 and -2. Neuroreport 8:3131–3135.
    MedlineWeb of Science
  28. ↵
    1. Tseng LF,
    2. Narita M,
    3. Suganuma C,
    4. Mizoguchi H,
    5. Ohsawa M,
    6. Nagase H,
    7. Kampine JP
    (2000) Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse. J Pharmacol Exp Ther 292:576–583.
    Abstract/FREE Full Text
  29. ↵
    1. Wahlestedt C
    (1993) Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol Sci 15:42–46.
  30. ↵
    1. Wu HE,
    2. Hung KC,
    3. Mizoguchi H,
    4. Fujimoto JM,
    5. Tseng LF
    (2001) Acute antinociceptive tolerance and asymmetric cross-tolerance between endomorphin-1 and endomorphin-2 given intracerebroventricularly in the mouse. J Pharmacol Exp Ther 299:1120–1125.
    Abstract/FREE Full Text
  31. ↵
    1. Zadina JE,
    2. Hackler L,
    3. Ge L-J,
    4. Kastin AJ
    (1997) A potent and selective endogenous agonist for the μ-opioid receptor. Nature (Lond) 386:499–502.
    CrossRefMedline
« Previous | Next Article »Table of Contents

This Article

  1. doi: 10.1124/jpet.102.038810 JPET November 1, 2002 vol. 303 no. 2 867-873
  1. AbstractFree
  2. » Full Text
  3. Full Text (PDF)

Classifications

Responses

  1. Submit a response
  2. No responses published

Navigate This Article

Current Issue

  1. November 2009, 331 (2)
  1. Current Issue
  1. Alert me to new issues of JPET